I
IGC Pharma, Inc. (IGC)
ASE – Real Time Price. Currency in USD
0.30
-0.01 (-2.15%)
At close: May 12, 2026, 4:00 PM EDT
0.31
+0.01 (3.91%)
After-hours: May 12, 2026, 7:58 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
ASE – Real Time Price. Currency in USD
0.30
-0.01 (-2.15%)
At close: May 12, 2026, 4:00 PM EDT
0.31
+0.01 (3.91%)
After-hours: May 12, 2026, 7:58 PM EDT
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer’s disease in the United States and Colombia. The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer’s disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
| Name | Position |
|---|---|
| Benysh Qureshi Esq., M.B.A. | Director of Operations |
| Mr. Ram Mukunda | Founder, President, CEO & Director |
| Mr. Rohit Goel CPA, M.B.A. | Director of Accounting & Senior Director |
| Ms. Claudia Grimaldi | VP, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director |
| Susana Salgar | Sales Manager |
| Date | Type | Document |
|---|---|---|
| 2026-04-20 | 8-K | igc8k200426.htm |
| 2026-03-30 | 8-K | igc8k033026.htm |
| 2026-03-18 | 10-KT | igc10kt123125.htm |
| 2026-03-12 | 8-K | igc8k031126.htm |
| 2026-01-02 | 8-K | igc8k010226.htm |
| 2025-12-15 | 8-K | igc8k121525.htm |
| 2025-12-04 | CORRESP | filename1.htm |
| 2025-12-03 | S-3/A | igcs3a112325.htm |
| 2025-11-17 | S-3 | igcs3111425.htm |
| 2025-11-14 | S-8 | igcs8103125.htm |